Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta--(Newsfile Corp. - November 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 59,693 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees.The DSUs will all vest on November 18, 2027. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days...